HC Wainwright Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price

Eton Pharmaceuticals (NASDAQ:ETON) had its price target raised by stock analysts at HC Wainwright from $70.00 to $80.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright‘s target price would indicate a potential upside of 69.67% from the company’s previous close.

ETON has been the topic of a number of other research reports. Canaccord Genuity Group boosted their price target on Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. Weiss Ratings raised shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. B. Riley Financial reiterated a “buy” rating and issued a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Zacks Research raised shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. Finally, Craig Hallum reissued a “buy” rating and set a $78.00 target price on shares of Eton Pharmaceuticals in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Eton Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $74.00.

Eton Pharmaceuticals Stock Down 7.0%

Shares of ETON stock opened at $47.15 on Friday. Eton Pharmaceuticals has a 1-year low of $14.27 and a 1-year high of $66.37. The stock’s fifty day moving average price is $54.92 and its 200 day moving average price is $36.26. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30. The company has a market cap of $1.35 billion, a price-to-earnings ratio of 124.08 and a beta of 0.89.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, November 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.19. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. The company had revenue of $57.93 million for the quarter, compared to analyst estimates of $41.98 million. On average, research analysts expect that Eton Pharmaceuticals will post 1.13 earnings per share for the current fiscal year.

Insider Transactions at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, Director Paul V. Maier sold 50,000 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the sale, the director owned 59,745 shares in the company, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Krempa sold 4,166 shares of the stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total value of $229,421.62. Following the completion of the transaction, the insider directly owned 43,381 shares in the company, valued at $2,388,991.67. This represents a 8.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 79,166 shares of company stock valued at $4,809,672. 16.49% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

Large investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Eton Pharmaceuticals in the second quarter valued at approximately $68,629,000. Nantahala Capital Management LLC purchased a new position in Eton Pharmaceuticals during the 2nd quarter worth approximately $42,569,426. Pillsbury Lake Capital LLC purchased a new position in Eton Pharmaceuticals during the 2nd quarter worth approximately $14,015,083. Panoramic Capital LLC purchased a new position in Eton Pharmaceuticals during the 2nd quarter worth approximately $7,537,000. Finally, Cannell Capital LLC acquired a new stake in Eton Pharmaceuticals during the 2nd quarter valued at approximately $6,181,041. Hedge funds and other institutional investors own 27.86% of the company’s stock.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Record Q3 product sales reached $57.9 million, up 158% year over year. Eton said it exceeded its $200 million annualized revenue run-rate goal five quarters ahead of schedule. Eton Q3 2026 financial results
• Positive Sentiment: The company raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to more than 40%, from more than 35%. Q3 adjusted EBITDA was $28.5 million, or 49% of revenue. Eton Q3 2026 financial results
• Positive Sentiment: Q3 fully diluted GAAP EPS was $1.06, versus the Zacks consensus estimate of $0.34; non-GAAP fully diluted EPS was $0.50. Revenue also exceeded analyst expectations of about $42 million. Eton Q3 earnings and revenues surpass estimates
• Positive Sentiment: Management highlighted growth and rare-disease pipeline progress, including preliminary ET-700 pilot-study results assessing copper absorption inhibition and gastrointestinal tolerability. The available report details do not specify the study findings. ET-700 pilot study announcement

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.